CL2015002680A1 - Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos - Google Patents

Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos

Info

Publication number
CL2015002680A1
CL2015002680A1 CL2015002680A CL2015002680A CL2015002680A1 CL 2015002680 A1 CL2015002680 A1 CL 2015002680A1 CL 2015002680 A CL2015002680 A CL 2015002680A CL 2015002680 A CL2015002680 A CL 2015002680A CL 2015002680 A1 CL2015002680 A1 CL 2015002680A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
ampk activator
serotonergic agent
agent
disease
Prior art date
Application number
CL2015002680A
Other languages
English (en)
Spanish (es)
Inventor
Chien-Hung Chen
Original Assignee
Als Mountain Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Als Mountain Llc filed Critical Als Mountain Llc
Publication of CL2015002680A1 publication Critical patent/CL2015002680A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
CL2015002680A 2013-03-15 2015-09-14 Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos CL2015002680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361793407P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002680A1 true CL2015002680A1 (es) 2016-09-02

Family

ID=51538303

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002680A CL2015002680A1 (es) 2013-03-15 2015-09-14 Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos

Country Status (16)

Country Link
US (1) US20140350064A1 (enExample)
EP (1) EP2983473A4 (enExample)
JP (1) JP2016513734A (enExample)
KR (1) KR20160005341A (enExample)
CN (1) CN105636438A (enExample)
AR (1) AR095631A1 (enExample)
AU (1) AU2014227807B2 (enExample)
BR (1) BR112015023922A2 (enExample)
CA (1) CA2909633A1 (enExample)
CL (1) CL2015002680A1 (enExample)
HK (1) HK1222297A1 (enExample)
IL (1) IL241587B (enExample)
MX (1) MX2015012760A (enExample)
RU (1) RU2015143438A (enExample)
TW (1) TW201444552A (enExample)
WO (1) WO2014144130A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180071269A1 (en) * 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
WO2017018752A1 (ko) * 2015-07-29 2017-02-02 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
KR101663543B1 (ko) * 2015-07-29 2016-10-07 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
EP3328494A4 (en) 2015-08-01 2019-04-03 Stephen J. Petti COMPOSITIONS AND METHODS FOR COMBINING PHARMACOLOGICAL TREATMENTS TO INDUCTION EXTENDED, Mild Acceptance of BODY CORE TEMPERATURE
CN105541665A (zh) * 2016-02-18 2016-05-04 江苏大学 一种抗肿瘤药物化合物及制备方法和应用
KR101838622B1 (ko) * 2016-09-20 2018-03-14 김브라이언 아디포넥틴 수용체에 대한 작용제 펩타이드
WO2018067685A1 (en) * 2016-10-05 2018-04-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule ampk activators
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CA3047451A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
CN107252425A (zh) * 2017-07-12 2017-10-17 上海华堇生物技术有限责任公司 去氢延胡索素的药物用途
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
CN108159044A (zh) * 2018-02-26 2018-06-15 华中科技大学 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN111892516A (zh) * 2018-08-08 2020-11-06 中国人民解放军总医院 抗肿瘤化合物
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN109771424B (zh) * 2019-03-11 2021-03-16 马慧 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
US12428378B2 (en) 2019-09-10 2025-09-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated AMPK protein
CN110559298A (zh) * 2019-10-28 2019-12-13 中国药科大学 一种天然化合物Egenine用于制备抗肾纤维化药物的用途
WO2021086133A1 (ko) * 2019-10-31 2021-05-06 (주)제이디바이오사이언스 삼환식 화합물 및 이의 약학적 용도
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use
CN116730981B (zh) * 2020-07-22 2024-07-02 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
IL305262A (en) 2021-03-10 2023-10-01 Jnana Therapeutics Inc Small molecule inhibitors of mammalian SLC6A19 function
JP2024527574A (ja) 2021-07-07 2024-07-25 テラン バイオサイエンシズ インコーポレイテッド Ｎ，ｎ－ジメチルトリプタミン及び関連する幻覚剤ならびにその使用
EP4429672A4 (en) 2021-11-12 2025-04-30 Terran Biosciences Inc. PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF
CN120659601A (zh) * 2022-12-05 2025-09-16 恩维达治疗公司 用于治疗瘙痒的诺卡酮

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
EP1762234A4 (en) * 2004-06-28 2010-05-05 Kao Corp AMPK AKTIVATOR
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7754700B2 (en) * 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
EP2118279B1 (en) * 2007-01-16 2017-11-22 Ipintl, Llc Novel composition for treating metabolic syndrome
US20120232003A1 (en) * 2009-03-13 2012-09-13 Takahashi Joseph S Compositions and methods for diabetes treatment
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition

Also Published As

Publication number Publication date
HK1222297A1 (zh) 2017-06-30
TW201444552A (zh) 2014-12-01
BR112015023922A2 (pt) 2017-07-18
AU2014227807B2 (en) 2018-03-08
CN105636438A (zh) 2016-06-01
MX2015012760A (es) 2016-06-17
AU2014227807A1 (en) 2015-11-05
EP2983473A4 (en) 2016-11-23
WO2014144130A3 (en) 2015-02-05
KR20160005341A (ko) 2016-01-14
AR095631A1 (es) 2015-10-28
WO2014144130A2 (en) 2014-09-18
RU2015143438A (ru) 2017-04-21
EP2983473A2 (en) 2016-02-17
JP2016513734A (ja) 2016-05-16
US20140350064A1 (en) 2014-11-27
CA2909633A1 (en) 2014-09-18
IL241587B (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CL2015002680A1 (es) Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX346861B (es) Metodos de tratamiento de carcinoma hepato celular.
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
CR11723A (es) Agente para tratar enfermedad
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
AR092925A1 (es) Derivados de exendina-4 como agonistas duales de glp1 / glucagon
ECSP13012661A (es) Composición farmacéutica, métodos de tratamiento y usos de la misma.
CO2017006308A2 (es) Derivados de glucagón
ES2570958T3 (es) Composición para el tratamiento de la fístula
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
DOP2016000253A (es) Nuevos compuestos
MX2015014589A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
CL2011002650A1 (es) Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson.
MX376496B (es) Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
MX2017009325A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.